Compare Incyte Corporation (INCY) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ON Holding AG — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while ON Holding AG trades at $37.67 (market cap $12.55B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| INCY | ONON | |
|---|---|---|
Market Cap | $23.11B | $12.55B |
Sector | Health | Technology |
52-Week High | $118.52 | $53.21 |
52-Week Low | $67.38 | $31.88 |
Enterprise Value | $19.13B | $11.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
ONON trades at $37.65, up 1.21% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 63.88% gross margin and has beaten earnings estimates for three consecutive quarters. Revenue reached $3.01B in 2025, with net income of $203.70M. Analyst sentiment is overwhelmingly positive, with 76.92% recommending Buy.
The outlook remains favorable due to consistent earnings beats and projected revenue growth to $3.1B in 2026. Risks include high valuation multiples like a P/E of 40.14 and competitive pressures. The consensus price target of $47.33 suggests 25.7% upside, but investors should monitor execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
